23:15 , Dec 7, 2018 |  BioCentury  |  Emerging Company Profile

ADCendo: entering tumors via MRC2

ADCendo ApS is developing an antibody-drug conjugate against mannose receptor C type 2 (MRC2; UPARAP) that could treat cancers at lower doses and with less toxicity than other ADCs, due to the target’s enriched cancer...
22:59 , Nov 30, 2018 |  BioCentury  |  Emerging Company Profile

Afyx: Mucosal drug delivery

Afyx Therapeutics is developing bioadhesive patches for mucosal drug delivery to address diseases that are inadequately treated by topical agents. Diseases affecting topically accessible mucosal sites, such as the buccal mucosa, are difficult to treat...
18:20 , Aug 31, 2018 |  BC Week In Review  |  Company News

Novo acquires Ziylo in quest for glucose-sensitive insulin

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) acquired Ziylo Ltd. (Bristol, U.K.), giving the pharma a platform that could help it develop a glucose-responsive insulin. Novo has identified glucose-sensitive insulin as an important innovative area for...
17:56 , Aug 29, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms; imaging

TECHNOLOGY: Structural analyses; other An electron microscopy-based method for identifying epitopes that elicit potent neutralizing antibodies could be used to guide the development of vaccines for infectious diseases. The method involves six steps: digesting animal-...
15:38 , Aug 17, 2018 |  BC Extra  |  Company News

Novo acquires Ziylo in quest for glucose-sensitive insulin

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) acquired Ziylo Ltd. (Bristol, U.K.), giving the pharma a platform that could help it develop a glucose-responsive insulin. Novo has identified glucose-sensitive insulin as an important innovative area for...
19:09 , Aug 7, 2018 |  BC Extra  |  Company News

Management tracks: GSK, J&J, Denali

GlaxoSmithKline plc (NYSE:GSK; LSE:GSK) hired Iain Mackay as CFO and executive director. Mackay, who is group finance director at HSBC, will join GSK on Jan. 14, 2019 as CFO designate and take formal accountability as...
22:42 , Jun 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Trypanosome In vitro studies identified tetrahydrophthalazinone-based inhibitors of T. brucei PDEB1 that could help treat African trypanosomiasis. Chemical synthesis and in vitro activity and cell division assays of tetrahydrophthalazinone analogs yielded two compounds that...
23:30 , May 7, 2018 |  BC Extra  |  Preclinical News

CRISPR platforms edit genome-wide at single-base level

Two studies in Nature Biotechnology describe CRISPR-Cas9-based techniques can produce trackable edits at single nucleotide resolution in eukaryotic cells. The methods stand to make genetic screens more precise and efficient. In eukaryotic cells, double-stranded DNA...
23:31 , May 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus; viral infection Cell culture studies suggest two sialylated IGHA1 isotype mAbs targeting HA could help treat influenza and Newcastle disease. The IGHA1 isotype mAbs consist of the variable regions of two previously...
20:47 , Feb 9, 2018 |  BC Extra  |  Company News

Novo gains European approval for diabetes drug Ozempic

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) said the European Commission approved subcutaneous Ozempic semaglutide (NN9535) to treat Type II diabetes in adults. Novo plans to launch the therapy next half. The product is indicated for use...